Sulfacetamide

• Catalog No.: DB00634
• CAS Number: 144-80-9
• M. F.: C8H10N2O3S
• M. W.: 214.2416

SYNONYMS

• IUPAC name: N-(4-aminobenzenesulfonyl)acetamide
• IUPAC Traditional name: N-(4-aminobenzenesulfonyl)acetamide
• Brand Name: P-Aminobenzenesulfonoacetamide; Acetosulfamine; Steri-Units Sulfacetamide; Albucid; Sebizon; Bleph-10; Formosulfacetamide; Isopto Cetamide; N-Acetylsulfanilamide; N-Acetylsulfanilamine; Oclucid; P-Aminobenzenesulfonacetamide; Sulamyd; Sulfacet; Sulfacetamide Sodium; Urosulfon; Acetosulfamin; Albamine; Alesten; Gyne-Sulf; Klaron; N-Sulfanilylacetamide; N-Sulphanilylacetamide; Ocusulf-10; Op-Sulfa 30; Ophthacet; Ophthel-S; Region; Sodium Sulfacetamide; Steramide; Sulf-15; Sulfacyl; Sulfair; Sulfair 10; Sulfair 15; Sulfamide; Sulfanilacetamide; Sulfex; Sulphacetamide Sodium; Trysul; Acetocid; Ak-Sulf; Bleph-10 Liquifilm; Cetamide; I-Sulfacet; Isopto-Cetamide; N'-Acetylsulfanilamide; Sodium Sulamyd; Sulf-10; Sulfacel-15; Sulfacetamide Sodium Anhydrous; Sulfacetamide Sodium Usp; Sulfacetimide; Sulfair Forte; Sulfair-15; Sulfanilazetamid; Sulphacetamide; Sulphasil; Sulten-10; Sultrin; Urosulfone

DATABASE IDS

• CAS Number: 144-80-9
• PubChem SID: 46504544
• PubChem CID: 5320

PROPERTIES

• Hydrophobicity(logP): -0.6
• Solubility: 1.25E+004 mg/L

DETAILS

Description (English)

• Drug Groups: approved
• Description: An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections. [PubChem]
• Indication: For the treatment of bacterial vaginitis, keratitis, acute conjunctivitis, and blepharitis.
• Pharmacology: Sulfacetamide is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
• Toxicity: Oral LD₅₀ Mouse : 16500 mg/kg. Side effects include moderate to severe erythema (redness) and moderate edema (raised kin), nausea, vomiting, headache, dizziness, and tiredness. Higher exposure causes unconsciousness.
• Affected Organisms: Enteric bacteria and other eubacteria
• Half Life: 7-12.8 hours
• References: Hull CA, Johnson SM: A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis. 2004 Jun;73(6):425-9. [Pubmed] ; Del Rosso JQ: Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004 Jan;73(1 Suppl):29-33. [Pubmed] ; Roth HW, Leimbeck R, Sonnenschein B, Anger CB, Weber S: [The effective antibacterial spectrum of sulfacetamide] Klin Monatsbl Augenheilkd. 1992 Mar;200(3):182-6. [Pubmed]
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com

REFERENCES

• Hull CA, Johnson SM: A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis. 2004 Jun;73(6):425-9. Pubmed
• Del Rosso JQ: Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004 Jan;73(1 Suppl):29-33. Pubmed
• Roth HW, Leimbeck R, Sonnenschein B, Anger CB, Weber S: [The effective antibacterial spectrum of sulfacetamide] Klin Monatsbl Augenheilkd. 1992 Mar;200(3):182-6. Pubmed